Tradestie Institutional Equity Comparison Engine
IONX vs ABUS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABUS Overall Edge
ABUS Captures Institutional Edge (4โ0 Pillars ยท 10โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Arbutus Biopharma Corporation Common Stock (ABUS) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, IONX trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ABUS at 10.2x Forward P/E and 80.1% operating margin (-43.5% YoY). In options structure, IONX sits in UNCLASSIFIED (4th %ile IV; Dealer Gamma Walls on Pro) against ABUS sits in CONSOLIDATION (28th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
ABUS
IONX N/M vs ABUS 10.2x Fwd P/E
Growth & Margin Winner
ABUS
Op Margin N/A vs 80.1% ยท YoY N/A vs -43.5%
Momentum & Technical Winner
ABUS
1Y -84.5% vs -11.4% ยท 52W Pos 0% vs 28%
Options & Structure Winner
ABUS
UNCLASSIFIED (4th %ile IV) vs CONSOLIDATION (28th %ile IV)
IONX
NASDAQ
Defiance Daily Target 2X Long IONQ ETF
Institutional Equity
$8.27
-16.55% 1D
Market Cap
N/A
1M Return
-36.82%
1Y Return
-84.51%
Forward P/E
N/M
Unified AI Score
48.8 / 100
HOLD
Tech 45.0
Fund 51.0
Flow 50.0
Mom 64.0
ABUS
NASDAQ
Arbutus Biopharma Corporation Common Stock
Pharmaceutical Preparations
$4.04
-1.22% 1D
Market Cap
$627.0M
1M Return
-4.27%
1Y Return
-11.4%
Forward P/E
10.2x
Unified AI Score
56.1 / 100
HOLD
Tech 72.0
Fund 64.0
Flow 68.0
Mom 53.7
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
IONX -84.51%
ABUS -11.4%
Spread: +73.11 pp (ABUS Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
IONX TTM Op. Margin: N/A
ABUS TTM Op. Margin: 80.1%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IONX vs ABUS. Trailing 12-month operating profitability (IONX N/A vs ABUS 80.1%) and valuation multiples (IONX N/M vs ABUS 10.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IONX | ABUS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $627.0M | Larger Scale | ABUS |
| Trailing P/E Ratio Valuation | N/M | 3.6x | Lower Multiple | ABUS |
| Forward P/E Ratio Valuation | N/M | 10.2x | Lower Multiple | ABUS |
| Revenue Growth (YoY) Growth | N/A | -43.5% | Higher Growth | ABUS |
| Operating Margin (TTM) Profitability | N/A | 80.1% | Higher Margin | ABUS |
| Net Profit Margin Profitability | N/A | 121.2% | Higher Margin | ABUS |
| Return on Equity (ROE) Capital Efficiency | N/A | 269.6% | Higher ROE | ABUS |
| 52-Week Range Position Momentum | 0% ($8โ$108) | 28% ($4โ$5) | Stronger Trend | ABUS |
| Beta / 30D Volatility Risk Regime | 6.79ฮฒ ยท 232% Vol | 1.20ฮฒ ยท 51% Vol | Lower Realized Risk | ABUS |
| Unified Institutional Score Composite Signal | 48.8 / 100 (HOLD) | 56.1 / 100 (HOLD) | Higher Composite | ABUS |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full IONX vs ABUS Buy Guide
IONX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
4th %ile
IV Regime
Compressed (<25th %ile)
ABUS
CONSOLIDATION
92d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
28th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither IONX nor ABUS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.